Pharma & Healthcare
Global PCSK9 Targeted Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031
- Nov 04, 25
- ID: 565002
- Pages: 111
- Figures: 129
- Views: 3
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global PCSK9 Targeted Drugs market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Regeneron Pharmaceuticals
Sanofi
Novartis
Innovent Biologics
Amgen
Segment by Type
Alirocumab
Evolocumab
Tafolecimab
Inclisiran
Segment by Application
Hypercholesterolemia
Combined Hyperlipidemia
Heart Disease and Stroke Prevention
Other
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the PCSK9 Targeted Drugs study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global PCSK9 Targeted Drugs market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Regeneron Pharmaceuticals
Sanofi
Novartis
Innovent Biologics
Amgen
Segment by Type
Alirocumab
Evolocumab
Tafolecimab
Inclisiran
Segment by Application
Hypercholesterolemia
Combined Hyperlipidemia
Heart Disease and Stroke Prevention
Other
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the PCSK9 Targeted Drugs study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to PCSK9 Targeted Drugs: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global PCSK9 Targeted Drugs Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Alirocumab
1.2.3 Evolocumab
1.2.4 Tafolecimab
1.2.5 Inclisiran
1.3 Market Segmentation by Application
1.3.1 Global PCSK9 Targeted Drugs Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hypercholesterolemia
1.3.3 Combined Hyperlipidemia
1.3.4 Heart Disease and Stroke Prevention
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global PCSK9 Targeted Drugs Revenue Estimates and Forecasts 2020-2031
2.2 Global PCSK9 Targeted Drugs Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global PCSK9 Targeted Drugs Sales Estimates and Forecasts 2020-2031
2.4 Global PCSK9 Targeted Drugs Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global PCSK9 Targeted Drugs Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global PCSK9 Targeted Drugs Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Alirocumab Market Size by Manufacturers
3.5.2 Evolocumab Market Size by Manufacturers
3.5.3 Tafolecimab Market Size by Manufacturers
3.5.4 Inclisiran Market Size by Manufacturers
3.6 Global PCSK9 Targeted Drugs Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global PCSK9 Targeted Drugs Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global PCSK9 Targeted Drugs Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global PCSK9 Targeted Drugs Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global PCSK9 Targeted Drugs Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America PCSK9 Targeted Drugs Sales and Revenue by Type (2020-2031)
6.4 North America PCSK9 Targeted Drugs Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America PCSK9 Targeted Drugs Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe PCSK9 Targeted Drugs Sales and Revenue by Type (2020-2031)
7.4 Europe PCSK9 Targeted Drugs Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe PCSK9 Targeted Drugs Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific PCSK9 Targeted Drugs Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific PCSK9 Targeted Drugs Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific PCSK9 Targeted Drugs Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America PCSK9 Targeted Drugs Sales and Revenue by Type (2020-2031)
9.4 Central and South America PCSK9 Targeted Drugs Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America PCSK9 Targeted Drugs Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa PCSK9 Targeted Drugs Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa PCSK9 Targeted Drugs Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa PCSK9 Targeted Drugs Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Regeneron Pharmaceuticals
11.1.1 Regeneron Pharmaceuticals Corporation Information
11.1.2 Regeneron Pharmaceuticals Business Overview
11.1.3 Regeneron Pharmaceuticals PCSK9 Targeted Drugs Product Models, Descriptions and Specifications
11.1.4 Regeneron Pharmaceuticals PCSK9 Targeted Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Regeneron Pharmaceuticals PCSK9 Targeted Drugs Sales by Product in 2024
11.1.6 Regeneron Pharmaceuticals PCSK9 Targeted Drugs Sales by Application in 2024
11.1.7 Regeneron Pharmaceuticals PCSK9 Targeted Drugs Sales by Geographic Area in 2024
11.1.8 Regeneron Pharmaceuticals PCSK9 Targeted Drugs SWOT Analysis
11.1.9 Regeneron Pharmaceuticals Recent Developments
11.2 Sanofi
11.2.1 Sanofi Corporation Information
11.2.2 Sanofi Business Overview
11.2.3 Sanofi PCSK9 Targeted Drugs Product Models, Descriptions and Specifications
11.2.4 Sanofi PCSK9 Targeted Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Sanofi PCSK9 Targeted Drugs Sales by Product in 2024
11.2.6 Sanofi PCSK9 Targeted Drugs Sales by Application in 2024
11.2.7 Sanofi PCSK9 Targeted Drugs Sales by Geographic Area in 2024
11.2.8 Sanofi PCSK9 Targeted Drugs SWOT Analysis
11.2.9 Sanofi Recent Developments
11.3 Novartis
11.3.1 Novartis Corporation Information
11.3.2 Novartis Business Overview
11.3.3 Novartis PCSK9 Targeted Drugs Product Models, Descriptions and Specifications
11.3.4 Novartis PCSK9 Targeted Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Novartis PCSK9 Targeted Drugs Sales by Product in 2024
11.3.6 Novartis PCSK9 Targeted Drugs Sales by Application in 2024
11.3.7 Novartis PCSK9 Targeted Drugs Sales by Geographic Area in 2024
11.3.8 Novartis PCSK9 Targeted Drugs SWOT Analysis
11.3.9 Novartis Recent Developments
11.4 Innovent Biologics
11.4.1 Innovent Biologics Corporation Information
11.4.2 Innovent Biologics Business Overview
11.4.3 Innovent Biologics PCSK9 Targeted Drugs Product Models, Descriptions and Specifications
11.4.4 Innovent Biologics PCSK9 Targeted Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Innovent Biologics PCSK9 Targeted Drugs Sales by Product in 2024
11.4.6 Innovent Biologics PCSK9 Targeted Drugs Sales by Application in 2024
11.4.7 Innovent Biologics PCSK9 Targeted Drugs Sales by Geographic Area in 2024
11.4.8 Innovent Biologics PCSK9 Targeted Drugs SWOT Analysis
11.4.9 Innovent Biologics Recent Developments
11.5 Amgen
11.5.1 Amgen Corporation Information
11.5.2 Amgen Business Overview
11.5.3 Amgen PCSK9 Targeted Drugs Product Models, Descriptions and Specifications
11.5.4 Amgen PCSK9 Targeted Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Amgen PCSK9 Targeted Drugs Sales by Product in 2024
11.5.6 Amgen PCSK9 Targeted Drugs Sales by Application in 2024
11.5.7 Amgen PCSK9 Targeted Drugs Sales by Geographic Area in 2024
11.5.8 Amgen PCSK9 Targeted Drugs SWOT Analysis
11.5.9 Amgen Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 PCSK9 Targeted Drugs Industry Chain
12.2 PCSK9 Targeted Drugs Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 PCSK9 Targeted Drugs Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 PCSK9 Targeted Drugs Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 PCSK9 Targeted Drugs Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global PCSK9 Targeted Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
1.1 Introduction to PCSK9 Targeted Drugs: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global PCSK9 Targeted Drugs Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Alirocumab
1.2.3 Evolocumab
1.2.4 Tafolecimab
1.2.5 Inclisiran
1.3 Market Segmentation by Application
1.3.1 Global PCSK9 Targeted Drugs Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hypercholesterolemia
1.3.3 Combined Hyperlipidemia
1.3.4 Heart Disease and Stroke Prevention
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global PCSK9 Targeted Drugs Revenue Estimates and Forecasts 2020-2031
2.2 Global PCSK9 Targeted Drugs Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global PCSK9 Targeted Drugs Sales Estimates and Forecasts 2020-2031
2.4 Global PCSK9 Targeted Drugs Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global PCSK9 Targeted Drugs Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global PCSK9 Targeted Drugs Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Alirocumab Market Size by Manufacturers
3.5.2 Evolocumab Market Size by Manufacturers
3.5.3 Tafolecimab Market Size by Manufacturers
3.5.4 Inclisiran Market Size by Manufacturers
3.6 Global PCSK9 Targeted Drugs Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global PCSK9 Targeted Drugs Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global PCSK9 Targeted Drugs Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global PCSK9 Targeted Drugs Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global PCSK9 Targeted Drugs Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America PCSK9 Targeted Drugs Sales and Revenue by Type (2020-2031)
6.4 North America PCSK9 Targeted Drugs Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America PCSK9 Targeted Drugs Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe PCSK9 Targeted Drugs Sales and Revenue by Type (2020-2031)
7.4 Europe PCSK9 Targeted Drugs Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe PCSK9 Targeted Drugs Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific PCSK9 Targeted Drugs Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific PCSK9 Targeted Drugs Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific PCSK9 Targeted Drugs Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America PCSK9 Targeted Drugs Sales and Revenue by Type (2020-2031)
9.4 Central and South America PCSK9 Targeted Drugs Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America PCSK9 Targeted Drugs Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa PCSK9 Targeted Drugs Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa PCSK9 Targeted Drugs Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa PCSK9 Targeted Drugs Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Regeneron Pharmaceuticals
11.1.1 Regeneron Pharmaceuticals Corporation Information
11.1.2 Regeneron Pharmaceuticals Business Overview
11.1.3 Regeneron Pharmaceuticals PCSK9 Targeted Drugs Product Models, Descriptions and Specifications
11.1.4 Regeneron Pharmaceuticals PCSK9 Targeted Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Regeneron Pharmaceuticals PCSK9 Targeted Drugs Sales by Product in 2024
11.1.6 Regeneron Pharmaceuticals PCSK9 Targeted Drugs Sales by Application in 2024
11.1.7 Regeneron Pharmaceuticals PCSK9 Targeted Drugs Sales by Geographic Area in 2024
11.1.8 Regeneron Pharmaceuticals PCSK9 Targeted Drugs SWOT Analysis
11.1.9 Regeneron Pharmaceuticals Recent Developments
11.2 Sanofi
11.2.1 Sanofi Corporation Information
11.2.2 Sanofi Business Overview
11.2.3 Sanofi PCSK9 Targeted Drugs Product Models, Descriptions and Specifications
11.2.4 Sanofi PCSK9 Targeted Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Sanofi PCSK9 Targeted Drugs Sales by Product in 2024
11.2.6 Sanofi PCSK9 Targeted Drugs Sales by Application in 2024
11.2.7 Sanofi PCSK9 Targeted Drugs Sales by Geographic Area in 2024
11.2.8 Sanofi PCSK9 Targeted Drugs SWOT Analysis
11.2.9 Sanofi Recent Developments
11.3 Novartis
11.3.1 Novartis Corporation Information
11.3.2 Novartis Business Overview
11.3.3 Novartis PCSK9 Targeted Drugs Product Models, Descriptions and Specifications
11.3.4 Novartis PCSK9 Targeted Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Novartis PCSK9 Targeted Drugs Sales by Product in 2024
11.3.6 Novartis PCSK9 Targeted Drugs Sales by Application in 2024
11.3.7 Novartis PCSK9 Targeted Drugs Sales by Geographic Area in 2024
11.3.8 Novartis PCSK9 Targeted Drugs SWOT Analysis
11.3.9 Novartis Recent Developments
11.4 Innovent Biologics
11.4.1 Innovent Biologics Corporation Information
11.4.2 Innovent Biologics Business Overview
11.4.3 Innovent Biologics PCSK9 Targeted Drugs Product Models, Descriptions and Specifications
11.4.4 Innovent Biologics PCSK9 Targeted Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Innovent Biologics PCSK9 Targeted Drugs Sales by Product in 2024
11.4.6 Innovent Biologics PCSK9 Targeted Drugs Sales by Application in 2024
11.4.7 Innovent Biologics PCSK9 Targeted Drugs Sales by Geographic Area in 2024
11.4.8 Innovent Biologics PCSK9 Targeted Drugs SWOT Analysis
11.4.9 Innovent Biologics Recent Developments
11.5 Amgen
11.5.1 Amgen Corporation Information
11.5.2 Amgen Business Overview
11.5.3 Amgen PCSK9 Targeted Drugs Product Models, Descriptions and Specifications
11.5.4 Amgen PCSK9 Targeted Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Amgen PCSK9 Targeted Drugs Sales by Product in 2024
11.5.6 Amgen PCSK9 Targeted Drugs Sales by Application in 2024
11.5.7 Amgen PCSK9 Targeted Drugs Sales by Geographic Area in 2024
11.5.8 Amgen PCSK9 Targeted Drugs SWOT Analysis
11.5.9 Amgen Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 PCSK9 Targeted Drugs Industry Chain
12.2 PCSK9 Targeted Drugs Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 PCSK9 Targeted Drugs Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 PCSK9 Targeted Drugs Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 PCSK9 Targeted Drugs Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global PCSK9 Targeted Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global PCSK9 Targeted Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global PCSK9 Targeted Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global PCSK9 Targeted Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global PCSK9 Targeted Drugs Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global PCSK9 Targeted Drugs Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global PCSK9 Targeted Drugs Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global PCSK9 Targeted Drugs Sales by Region (2020-2025) & (K Units)
Table 8. Global PCSK9 Targeted Drugs Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global PCSK9 Targeted Drugs Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global PCSK9 Targeted Drugs Sales Share by Manufacturers (2020-2025)
Table 12. Global PCSK9 Targeted Drugs Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global PCSK9 Targeted Drugs Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global PCSK9 Targeted Drugs by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PCSK9 Targeted Drugs as of 2024)
Table 16. Global PCSK9 Targeted Drugs Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global PCSK9 Targeted Drugs Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers PCSK9 Targeted Drugs Manufacturing Base and Headquarters
Table 19. Global PCSK9 Targeted Drugs Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global PCSK9 Targeted Drugs Sales by Type (2020-2025) & (K Units)
Table 23. Global PCSK9 Targeted Drugs Sales by Type (2026-2031) & (K Units)
Table 24. Global PCSK9 Targeted Drugs Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global PCSK9 Targeted Drugs Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global PCSK9 Targeted Drugs ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global PCSK9 Targeted Drugs Sales by Application (2020-2025) & (K Units)
Table 29. Global PCSK9 Targeted Drugs Sales by Application (2026-2031) & (K Units)
Table 30. PCSK9 Targeted Drugs High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global PCSK9 Targeted Drugs Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global PCSK9 Targeted Drugs Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global PCSK9 Targeted Drugs ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America PCSK9 Targeted Drugs Growth Accelerators and Market Barriers
Table 37. North America PCSK9 Targeted Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America PCSK9 Targeted Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe PCSK9 Targeted Drugs Growth Accelerators and Market Barriers
Table 40. Europe PCSK9 Targeted Drugs Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe PCSK9 Targeted Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific PCSK9 Targeted Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific PCSK9 Targeted Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific PCSK9 Targeted Drugs Growth Accelerators and Market Barriers
Table 45. Southeast Asia PCSK9 Targeted Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America PCSK9 Targeted Drugs Investment Opportunities and Key Challenges
Table 47. Central and South America PCSK9 Targeted Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa PCSK9 Targeted Drugs Investment Opportunities and Key Challenges
Table 49. Middle East and Africa PCSK9 Targeted Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Regeneron Pharmaceuticals Corporation Information
Table 51. Regeneron Pharmaceuticals Description and Major Businesses
Table 52. Regeneron Pharmaceuticals Product Models, Descriptions and Specifications
Table 53. Regeneron Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Regeneron Pharmaceuticals Sales Value Proportion by Product in 2024
Table 55. Regeneron Pharmaceuticals Sales Value Proportion by Application in 2024
Table 56. Regeneron Pharmaceuticals Sales Value Proportion by Geographic Area in 2024
Table 57. Regeneron Pharmaceuticals PCSK9 Targeted Drugs SWOT Analysis
Table 58. Regeneron Pharmaceuticals Recent Developments
Table 59. Sanofi Corporation Information
Table 60. Sanofi Description and Major Businesses
Table 61. Sanofi Product Models, Descriptions and Specifications
Table 62. Sanofi Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Sanofi Sales Value Proportion by Product in 2024
Table 64. Sanofi Sales Value Proportion by Application in 2024
Table 65. Sanofi Sales Value Proportion by Geographic Area in 2024
Table 66. Sanofi PCSK9 Targeted Drugs SWOT Analysis
Table 67. Sanofi Recent Developments
Table 68. Novartis Corporation Information
Table 69. Novartis Description and Major Businesses
Table 70. Novartis Product Models, Descriptions and Specifications
Table 71. Novartis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Novartis Sales Value Proportion by Product in 2024
Table 73. Novartis Sales Value Proportion by Application in 2024
Table 74. Novartis Sales Value Proportion by Geographic Area in 2024
Table 75. Novartis PCSK9 Targeted Drugs SWOT Analysis
Table 76. Novartis Recent Developments
Table 77. Innovent Biologics Corporation Information
Table 78. Innovent Biologics Description and Major Businesses
Table 79. Innovent Biologics Product Models, Descriptions and Specifications
Table 80. Innovent Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Innovent Biologics Sales Value Proportion by Product in 2024
Table 82. Innovent Biologics Sales Value Proportion by Application in 2024
Table 83. Innovent Biologics Sales Value Proportion by Geographic Area in 2024
Table 84. Innovent Biologics PCSK9 Targeted Drugs SWOT Analysis
Table 85. Innovent Biologics Recent Developments
Table 86. Amgen Corporation Information
Table 87. Amgen Description and Major Businesses
Table 88. Amgen Product Models, Descriptions and Specifications
Table 89. Amgen Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Amgen Sales Value Proportion by Product in 2024
Table 91. Amgen Sales Value Proportion by Application in 2024
Table 92. Amgen Sales Value Proportion by Geographic Area in 2024
Table 93. Amgen PCSK9 Targeted Drugs SWOT Analysis
Table 94. Amgen Recent Developments
Table 95. Key Raw Materials Distribution
Table 96. Raw Materials Key Suppliers
Table 97. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 98. Milestones in Production Technology Evolution
Table 99. Distributors List
Table 100. Market Trends and Market Evolution
Table 101. Market Drivers and Opportunities
Table 102. Market Challenges, Risks, and Restraints
Table 103. Research Programs/Design for This Report
Table 104. Key Data Information from Secondary Sources
Table 105. Key Data Information from Primary Sources
List of Figures
Figure 1. PCSK9 Targeted Drugs Product Picture
Figure 2. Global PCSK9 Targeted Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Alirocumab Product Picture
Figure 4. Evolocumab Product Picture
Figure 5. Tafolecimab Product Picture
Figure 6. Inclisiran Product Picture
Figure 7. Global PCSK9 Targeted Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 8. Hypercholesterolemia
Figure 9. Combined Hyperlipidemia
Figure 10. Heart Disease and Stroke Prevention
Figure 11. Other
Figure 12. PCSK9 Targeted Drugs Report Years Considered
Figure 13. Global PCSK9 Targeted Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global PCSK9 Targeted Drugs Revenue (2020-2031) & (US$ Million)
Figure 15. Global PCSK9 Targeted Drugs Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 16. Global PCSK9 Targeted Drugs Revenue Market Share by Region (2020-2031)
Figure 17. Global PCSK9 Targeted Drugs Sales (2020-2031) & (K Units)
Figure 18. Global PCSK9 Targeted Drugs Sales (CAGR) by Region (2020-2031) (K Units)
Figure 19. Global PCSK9 Targeted Drugs Sales Market Share by Region (2020-2031)
Figure 20. Top 5 and Top 10 Manufacturers PCSK9 Targeted Drugs Sales Volume Market Share in 2024
Figure 21. Global PCSK9 Targeted Drugs Revenue Market Share Ranking (2024)
Figure 22. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 23. Alirocumab Revenue Market Share by Manufacturer in 2024
Figure 24. Evolocumab Revenue Market Share by Manufacturer in 2024
Figure 25. Tafolecimab Revenue Market Share by Manufacturer in 2024
Figure 26. Inclisiran Revenue Market Share by Manufacturer in 2024
Figure 27. Global PCSK9 Targeted Drugs Sales Market Share by Type (2020-2031)
Figure 28. Global PCSK9 Targeted Drugs Revenue Market Share by Type (2020-2031)
Figure 29. Global PCSK9 Targeted Drugs Sales Market Share by Application (2020-2031)
Figure 30. Global PCSK9 Targeted Drugs Revenue Market Share by Application (2020-2031)
Figure 31. North America PCSK9 Targeted Drugs Sales YoY (2020-2031) & (K Units)
Figure 32. North America PCSK9 Targeted Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 33. North America Top 5 Manufacturers PCSK9 Targeted Drugs Sales Revenue (US$ Million) in 2024
Figure 34. North America PCSK9 Targeted Drugs Sales Volume (K Units) by Type (2020- 2031)
Figure 35. North America PCSK9 Targeted Drugs Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 36. North America PCSK9 Targeted Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 37. North America PCSK9 Targeted Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 38. US PCSK9 Targeted Drugs Revenue (2020-2031) & (US$ Million)
Figure 39. Canada PCSK9 Targeted Drugs Revenue (2020-2031) & (US$ Million)
Figure 40. Mexico PCSK9 Targeted Drugs Revenue (2020-2031) & (US$ Million)
Figure 41. Europe PCSK9 Targeted Drugs Sales YoY (2020-2031) & (K Units)
Figure 42. Europe PCSK9 Targeted Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 43. Europe Top 5 Manufacturers PCSK9 Targeted Drugs Sales Revenue (US$ Million) in 2024
Figure 44. Europe PCSK9 Targeted Drugs Sales Volume (K Units) by Type (2020-2031)
Figure 45. Europe PCSK9 Targeted Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 46. Europe PCSK9 Targeted Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 47. Europe PCSK9 Targeted Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 48. Germany PCSK9 Targeted Drugs Revenue (2020-2031) & (US$ Million)
Figure 49. France PCSK9 Targeted Drugs Revenue (2020-2031) & (US$ Million)
Figure 50. U.K. PCSK9 Targeted Drugs Revenue (2020-2031) & (US$ Million)
Figure 51. Italy PCSK9 Targeted Drugs Revenue (2020-2031) & (US$ Million)
Figure 52. Russia PCSK9 Targeted Drugs Revenue (2020-2031) & (US$ Million)
Figure 53. Asia-Pacific PCSK9 Targeted Drugs Sales YoY (2020-2031) & (K Units)
Figure 54. Asia-Pacific PCSK9 Targeted Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 55. Asia-Pacific Top 8 Manufacturers PCSK9 Targeted Drugs Sales Revenue (US$ Million) in 2024
Figure 56. Asia-Pacific PCSK9 Targeted Drugs Sales Volume (K Units) by Type (2020- 2031)
Figure 57. Asia-Pacific PCSK9 Targeted Drugs Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 58. Asia-Pacific PCSK9 Targeted Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 59. Asia-Pacific PCSK9 Targeted Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 60. Indonesia PCSK9 Targeted Drugs Revenue (2020-2031) & (US$ Million)
Figure 61. Japan PCSK9 Targeted Drugs Revenue (2020-2031) & (US$ Million)
Figure 62. South Korea PCSK9 Targeted Drugs Revenue (2020-2031) & (US$ Million)
Figure 63. China Taiwan PCSK9 Targeted Drugs Revenue (2020-2031) & (US$ Million)
Figure 64. India PCSK9 Targeted Drugs Revenue (2020-2031) & (US$ Million)
Figure 65. Central and South America PCSK9 Targeted Drugs Sales YoY (2020-2031) & (K Units)
Figure 66. Central and South America PCSK9 Targeted Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 67. Central and South America Top 5 Manufacturers PCSK9 Targeted Drugs Sales Revenue (US$ Million) in 2024
Figure 68. Central and South America PCSK9 Targeted Drugs Sales Volume (K Units) by Type (2021-2031)
Figure 69. Central and South America PCSK9 Targeted Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 70. Central and South America PCSK9 Targeted Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 71. Central and South America PCSK9 Targeted Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 72. Brazil PCSK9 Targeted Drugs Revenue (2020-2025) & (US$ Million)
Figure 73. Argentina PCSK9 Targeted Drugs Revenue (2020-2025) & (US$ Million)
Figure 74. Middle East, and Africa PCSK9 Targeted Drugs Sales YoY (2020-2031) & (K Units)
Figure 75. Middle East and Africa PCSK9 Targeted Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 76. Middle East and Africa Top 5 Manufacturers PCSK9 Targeted Drugs Sales Revenue (US$ Million) in 2024
Figure 77. Middle East and Africa PCSK9 Targeted Drugs Sales Volume (K Units) by Type (2021-2031)
Figure 78. South America PCSK9 Targeted Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 79. Middle East and Africa PCSK9 Targeted Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 80. Middle East and Africa PCSK9 Targeted Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 81. GCC Countries PCSK9 Targeted Drugs Revenue (2020-2025) & (US$ Million)
Figure 82. Turkey PCSK9 Targeted Drugs Revenue (2020-2025) & (US$ Million)
Figure 83. Egypt PCSK9 Targeted Drugs Revenue (2020-2025) & (US$ Million)
Figure 84. South Africa PCSK9 Targeted Drugs Revenue (2020-2025) & (US$ Million)
Figure 85. PCSK9 Targeted Drugs Industry Chain Mapping
Figure 86. Regional PCSK9 Targeted Drugs Manufacturing Base Distribution (%)
Figure 87. Global PCSK9 Targeted Drugs Production Market Share by Region (2020-2031)
Figure 88. PCSK9 Targeted Drugs Production Process
Figure 89. Regional PCSK9 Targeted Drugs Production Cost Structure
Figure 90. Channels of Distribution (Direct Vs Distribution)
Figure 91. Bottom-up and Top-down Approaches for This Report
Figure 92. Data Triangulation
Figure 93. Key Executives Interviewed
Table 1. Global PCSK9 Targeted Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global PCSK9 Targeted Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global PCSK9 Targeted Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global PCSK9 Targeted Drugs Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global PCSK9 Targeted Drugs Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global PCSK9 Targeted Drugs Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global PCSK9 Targeted Drugs Sales by Region (2020-2025) & (K Units)
Table 8. Global PCSK9 Targeted Drugs Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global PCSK9 Targeted Drugs Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global PCSK9 Targeted Drugs Sales Share by Manufacturers (2020-2025)
Table 12. Global PCSK9 Targeted Drugs Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global PCSK9 Targeted Drugs Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global PCSK9 Targeted Drugs by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PCSK9 Targeted Drugs as of 2024)
Table 16. Global PCSK9 Targeted Drugs Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global PCSK9 Targeted Drugs Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers PCSK9 Targeted Drugs Manufacturing Base and Headquarters
Table 19. Global PCSK9 Targeted Drugs Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global PCSK9 Targeted Drugs Sales by Type (2020-2025) & (K Units)
Table 23. Global PCSK9 Targeted Drugs Sales by Type (2026-2031) & (K Units)
Table 24. Global PCSK9 Targeted Drugs Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global PCSK9 Targeted Drugs Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global PCSK9 Targeted Drugs ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global PCSK9 Targeted Drugs Sales by Application (2020-2025) & (K Units)
Table 29. Global PCSK9 Targeted Drugs Sales by Application (2026-2031) & (K Units)
Table 30. PCSK9 Targeted Drugs High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global PCSK9 Targeted Drugs Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global PCSK9 Targeted Drugs Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global PCSK9 Targeted Drugs ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America PCSK9 Targeted Drugs Growth Accelerators and Market Barriers
Table 37. North America PCSK9 Targeted Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America PCSK9 Targeted Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe PCSK9 Targeted Drugs Growth Accelerators and Market Barriers
Table 40. Europe PCSK9 Targeted Drugs Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe PCSK9 Targeted Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific PCSK9 Targeted Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific PCSK9 Targeted Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific PCSK9 Targeted Drugs Growth Accelerators and Market Barriers
Table 45. Southeast Asia PCSK9 Targeted Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America PCSK9 Targeted Drugs Investment Opportunities and Key Challenges
Table 47. Central and South America PCSK9 Targeted Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa PCSK9 Targeted Drugs Investment Opportunities and Key Challenges
Table 49. Middle East and Africa PCSK9 Targeted Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Regeneron Pharmaceuticals Corporation Information
Table 51. Regeneron Pharmaceuticals Description and Major Businesses
Table 52. Regeneron Pharmaceuticals Product Models, Descriptions and Specifications
Table 53. Regeneron Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Regeneron Pharmaceuticals Sales Value Proportion by Product in 2024
Table 55. Regeneron Pharmaceuticals Sales Value Proportion by Application in 2024
Table 56. Regeneron Pharmaceuticals Sales Value Proportion by Geographic Area in 2024
Table 57. Regeneron Pharmaceuticals PCSK9 Targeted Drugs SWOT Analysis
Table 58. Regeneron Pharmaceuticals Recent Developments
Table 59. Sanofi Corporation Information
Table 60. Sanofi Description and Major Businesses
Table 61. Sanofi Product Models, Descriptions and Specifications
Table 62. Sanofi Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Sanofi Sales Value Proportion by Product in 2024
Table 64. Sanofi Sales Value Proportion by Application in 2024
Table 65. Sanofi Sales Value Proportion by Geographic Area in 2024
Table 66. Sanofi PCSK9 Targeted Drugs SWOT Analysis
Table 67. Sanofi Recent Developments
Table 68. Novartis Corporation Information
Table 69. Novartis Description and Major Businesses
Table 70. Novartis Product Models, Descriptions and Specifications
Table 71. Novartis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Novartis Sales Value Proportion by Product in 2024
Table 73. Novartis Sales Value Proportion by Application in 2024
Table 74. Novartis Sales Value Proportion by Geographic Area in 2024
Table 75. Novartis PCSK9 Targeted Drugs SWOT Analysis
Table 76. Novartis Recent Developments
Table 77. Innovent Biologics Corporation Information
Table 78. Innovent Biologics Description and Major Businesses
Table 79. Innovent Biologics Product Models, Descriptions and Specifications
Table 80. Innovent Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Innovent Biologics Sales Value Proportion by Product in 2024
Table 82. Innovent Biologics Sales Value Proportion by Application in 2024
Table 83. Innovent Biologics Sales Value Proportion by Geographic Area in 2024
Table 84. Innovent Biologics PCSK9 Targeted Drugs SWOT Analysis
Table 85. Innovent Biologics Recent Developments
Table 86. Amgen Corporation Information
Table 87. Amgen Description and Major Businesses
Table 88. Amgen Product Models, Descriptions and Specifications
Table 89. Amgen Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Amgen Sales Value Proportion by Product in 2024
Table 91. Amgen Sales Value Proportion by Application in 2024
Table 92. Amgen Sales Value Proportion by Geographic Area in 2024
Table 93. Amgen PCSK9 Targeted Drugs SWOT Analysis
Table 94. Amgen Recent Developments
Table 95. Key Raw Materials Distribution
Table 96. Raw Materials Key Suppliers
Table 97. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 98. Milestones in Production Technology Evolution
Table 99. Distributors List
Table 100. Market Trends and Market Evolution
Table 101. Market Drivers and Opportunities
Table 102. Market Challenges, Risks, and Restraints
Table 103. Research Programs/Design for This Report
Table 104. Key Data Information from Secondary Sources
Table 105. Key Data Information from Primary Sources
List of Figures
Figure 1. PCSK9 Targeted Drugs Product Picture
Figure 2. Global PCSK9 Targeted Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Alirocumab Product Picture
Figure 4. Evolocumab Product Picture
Figure 5. Tafolecimab Product Picture
Figure 6. Inclisiran Product Picture
Figure 7. Global PCSK9 Targeted Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 8. Hypercholesterolemia
Figure 9. Combined Hyperlipidemia
Figure 10. Heart Disease and Stroke Prevention
Figure 11. Other
Figure 12. PCSK9 Targeted Drugs Report Years Considered
Figure 13. Global PCSK9 Targeted Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global PCSK9 Targeted Drugs Revenue (2020-2031) & (US$ Million)
Figure 15. Global PCSK9 Targeted Drugs Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 16. Global PCSK9 Targeted Drugs Revenue Market Share by Region (2020-2031)
Figure 17. Global PCSK9 Targeted Drugs Sales (2020-2031) & (K Units)
Figure 18. Global PCSK9 Targeted Drugs Sales (CAGR) by Region (2020-2031) (K Units)
Figure 19. Global PCSK9 Targeted Drugs Sales Market Share by Region (2020-2031)
Figure 20. Top 5 and Top 10 Manufacturers PCSK9 Targeted Drugs Sales Volume Market Share in 2024
Figure 21. Global PCSK9 Targeted Drugs Revenue Market Share Ranking (2024)
Figure 22. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 23. Alirocumab Revenue Market Share by Manufacturer in 2024
Figure 24. Evolocumab Revenue Market Share by Manufacturer in 2024
Figure 25. Tafolecimab Revenue Market Share by Manufacturer in 2024
Figure 26. Inclisiran Revenue Market Share by Manufacturer in 2024
Figure 27. Global PCSK9 Targeted Drugs Sales Market Share by Type (2020-2031)
Figure 28. Global PCSK9 Targeted Drugs Revenue Market Share by Type (2020-2031)
Figure 29. Global PCSK9 Targeted Drugs Sales Market Share by Application (2020-2031)
Figure 30. Global PCSK9 Targeted Drugs Revenue Market Share by Application (2020-2031)
Figure 31. North America PCSK9 Targeted Drugs Sales YoY (2020-2031) & (K Units)
Figure 32. North America PCSK9 Targeted Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 33. North America Top 5 Manufacturers PCSK9 Targeted Drugs Sales Revenue (US$ Million) in 2024
Figure 34. North America PCSK9 Targeted Drugs Sales Volume (K Units) by Type (2020- 2031)
Figure 35. North America PCSK9 Targeted Drugs Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 36. North America PCSK9 Targeted Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 37. North America PCSK9 Targeted Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 38. US PCSK9 Targeted Drugs Revenue (2020-2031) & (US$ Million)
Figure 39. Canada PCSK9 Targeted Drugs Revenue (2020-2031) & (US$ Million)
Figure 40. Mexico PCSK9 Targeted Drugs Revenue (2020-2031) & (US$ Million)
Figure 41. Europe PCSK9 Targeted Drugs Sales YoY (2020-2031) & (K Units)
Figure 42. Europe PCSK9 Targeted Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 43. Europe Top 5 Manufacturers PCSK9 Targeted Drugs Sales Revenue (US$ Million) in 2024
Figure 44. Europe PCSK9 Targeted Drugs Sales Volume (K Units) by Type (2020-2031)
Figure 45. Europe PCSK9 Targeted Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 46. Europe PCSK9 Targeted Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 47. Europe PCSK9 Targeted Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 48. Germany PCSK9 Targeted Drugs Revenue (2020-2031) & (US$ Million)
Figure 49. France PCSK9 Targeted Drugs Revenue (2020-2031) & (US$ Million)
Figure 50. U.K. PCSK9 Targeted Drugs Revenue (2020-2031) & (US$ Million)
Figure 51. Italy PCSK9 Targeted Drugs Revenue (2020-2031) & (US$ Million)
Figure 52. Russia PCSK9 Targeted Drugs Revenue (2020-2031) & (US$ Million)
Figure 53. Asia-Pacific PCSK9 Targeted Drugs Sales YoY (2020-2031) & (K Units)
Figure 54. Asia-Pacific PCSK9 Targeted Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 55. Asia-Pacific Top 8 Manufacturers PCSK9 Targeted Drugs Sales Revenue (US$ Million) in 2024
Figure 56. Asia-Pacific PCSK9 Targeted Drugs Sales Volume (K Units) by Type (2020- 2031)
Figure 57. Asia-Pacific PCSK9 Targeted Drugs Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 58. Asia-Pacific PCSK9 Targeted Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 59. Asia-Pacific PCSK9 Targeted Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 60. Indonesia PCSK9 Targeted Drugs Revenue (2020-2031) & (US$ Million)
Figure 61. Japan PCSK9 Targeted Drugs Revenue (2020-2031) & (US$ Million)
Figure 62. South Korea PCSK9 Targeted Drugs Revenue (2020-2031) & (US$ Million)
Figure 63. China Taiwan PCSK9 Targeted Drugs Revenue (2020-2031) & (US$ Million)
Figure 64. India PCSK9 Targeted Drugs Revenue (2020-2031) & (US$ Million)
Figure 65. Central and South America PCSK9 Targeted Drugs Sales YoY (2020-2031) & (K Units)
Figure 66. Central and South America PCSK9 Targeted Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 67. Central and South America Top 5 Manufacturers PCSK9 Targeted Drugs Sales Revenue (US$ Million) in 2024
Figure 68. Central and South America PCSK9 Targeted Drugs Sales Volume (K Units) by Type (2021-2031)
Figure 69. Central and South America PCSK9 Targeted Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 70. Central and South America PCSK9 Targeted Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 71. Central and South America PCSK9 Targeted Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 72. Brazil PCSK9 Targeted Drugs Revenue (2020-2025) & (US$ Million)
Figure 73. Argentina PCSK9 Targeted Drugs Revenue (2020-2025) & (US$ Million)
Figure 74. Middle East, and Africa PCSK9 Targeted Drugs Sales YoY (2020-2031) & (K Units)
Figure 75. Middle East and Africa PCSK9 Targeted Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 76. Middle East and Africa Top 5 Manufacturers PCSK9 Targeted Drugs Sales Revenue (US$ Million) in 2024
Figure 77. Middle East and Africa PCSK9 Targeted Drugs Sales Volume (K Units) by Type (2021-2031)
Figure 78. South America PCSK9 Targeted Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 79. Middle East and Africa PCSK9 Targeted Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 80. Middle East and Africa PCSK9 Targeted Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 81. GCC Countries PCSK9 Targeted Drugs Revenue (2020-2025) & (US$ Million)
Figure 82. Turkey PCSK9 Targeted Drugs Revenue (2020-2025) & (US$ Million)
Figure 83. Egypt PCSK9 Targeted Drugs Revenue (2020-2025) & (US$ Million)
Figure 84. South Africa PCSK9 Targeted Drugs Revenue (2020-2025) & (US$ Million)
Figure 85. PCSK9 Targeted Drugs Industry Chain Mapping
Figure 86. Regional PCSK9 Targeted Drugs Manufacturing Base Distribution (%)
Figure 87. Global PCSK9 Targeted Drugs Production Market Share by Region (2020-2031)
Figure 88. PCSK9 Targeted Drugs Production Process
Figure 89. Regional PCSK9 Targeted Drugs Production Cost Structure
Figure 90. Channels of Distribution (Direct Vs Distribution)
Figure 91. Bottom-up and Top-down Approaches for This Report
Figure 92. Data Triangulation
Figure 93. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global UV Delayed Curing Adhesives Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Global Die-Casting Die Steel Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Global Adaptive Neuromodulation Therapy Devices Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232